Björklund Pharma

  • Home
  • Company
  • Science & Innovation
  • Media
  • Contact
    • Contact Form

Thymosin Beta 4 in Dry Eye Syndrome

July 16, 2022 By admin

Dry eye syndrome (DES) affects more than 30 million people in the US alone. DES is characterized by ocular surface inflammation. Consequently, patients can suffer from burning, irritation, severe discomfort, foreign body sensation, and blurry and decreased vision. Thymosin beta 4 (Tβ4) significantly improves signs and symptoms of dry eye without any toxic effects.

Current wound healing and anti-inflammatory treatment options for the cornea are limited, and some of the agents used may cause significant complications and side effects. Tβ4 promotes corneal epithelial cell migration, decreases the expression of corneal epithelial cytokines and chemokines (IL-1β and IL-8, respectively), and inhibits corneal PMN infiltration and adhesion to endothelium. Björklund Pharma AS focuses on Tβ4 product development.

PubMed articles: https://bit.ly/3Rw9BxC

Filed Under: Company News, Press & News, Research News

Recent Posts

  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment
  • Serum Zinc and Copper Levels in Autistic Children

Company News

  • A Possible New Medicine for Multiple Sclerosis?
  • Thymosin Beta 4 in Dry Eye Syndrome
  • The Role of Thymosin Beta 4 in COVID-19 Treatment
  • Zinc Deficiency: A Globally Widespread Ailment
  • Serum Zinc and Copper Levels in Autistic Children
  • Email
  • Facebook
  • Google+
  • LinkedIn
  • Twitter
  • YouTube

RSS CONEM News

  • Better Brain Health – We Are What We Eat
  • Nutritional Minerals and the Periodic Table
  • Semey Revisited: The legacy of nuclear testing in Kazakhstan
  • Environmental Radiation Exposure and Essential Hypertension in Semey, Kazakhstan
  • A Brief History of Fat, and Why We Hate It

Contact Us

Björklund Pharma AS
Toften 24
8610 Mo i Rana
Norway

Phone: +47 411 11 942
Email: info(at)bjorklundpharma.com

Copyright © 2022 Björklund Pharma AS